Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3837-3845

  Magda, Darren ^a   Lecane, Philip ^a   Miller, Richard A ^a   Lepp, Cheryl ^a   Miles, Dale ^a   Mesfin, Mimi ^a   Biaglow, John E ^b   Ho, Vincent V ^c   Chawannakul, Danny ^c   Nagpal, Shailender ^c   Karaman, Mazen W ^c   Hacia, Joseph G ^c  

^a PHARMACYCLICS INC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM TEXAPHYRIN; ISOPROTEIN; METALLOTHIONEIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG; ZINC ACETATE; ZINC TRANSPORTER; ZINC TRANSPORTER 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CELL DEATH; CLINICAL PATHWAY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSCRIPTION REGULATION; TUMOR CELL LINE; ZINC METABOLISM;

ACETATES; ANTINEOPLASTIC AGENTS; CADMIUM; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; LYMPHOMA, B-CELL; MALE; METALLOPORPHYRINS; NEOPLASMS; OXIDATION-REDUCTION; PROSTATIC NEOPLASMS; THIOCTIC ACID; ZINC; ZINC ACETATE;

EID: 20944432604     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4099     Document Type: Article

References (59)

1. Leonard SS, Bower JJ, Shi X. Metal-induced toxicity, carcinogenesis, mechanisms and cellular responses. Mol Cell Biochem 2004;255:3-10.
2. Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2003;95:1004-7.
3. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003;533:201-9.
4. Hasumi M, Suzuki K, Matsui H, Koike H, Ito K, Yamanaka H. Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues. Cancer Lett 2003;200:187-95.
5. Jayasurya A, Bay BH, Yap WM, Tan NG, Tan BK. Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. Carcinogenesis 2000;21:1809-12.
6. Kondoh M, Tasaki E, Araragi S, et al. Requirement of caspase and p38MAPK activation in zinc-induced apoptosis in human leukemia HL-60 cells. Eur J Biochem 2002;269:6204-11.
7. Kim CH, Kim JH, Moon SJ, et al. Pyrithione, a zinc ionophore, inhibits NF-κB activation. Biochem Biophys Res Commun 1999;259:505-9.
8. 2t-induced ERK activation mediated by reactive oxygen species causes cell death in differentiated PC12 cells. J Neurochem 2001;78:600-10.
9. Forbes IJ, Zalewski PD, Giannakis C. Role for zinc in a cellular response mediated by protein kinase C in human B lymphocytes. Exp Cell Res 1991;195:224-9.
10. Uzzo RG, Leavis P, Hatch W, et al. Zinc inhibits nuclear factor-κB activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res 2002;8:3579-83.
11. Cousins RJ, Blanchard RK, Popp MP, et al. A global view of the selectivity of zinc deprivation and excess on genes expressed in human THP-1 mononuclear cells. Proc Natl Acad Sci U S A 2003;100:6952-7.
12. Hecht D, Jung D, Prabhu VV, Munson PJ, Hoffman MP, Kleinman HK. Metallothionein promotes laminin-1-induced acinar differentiation in vitro and reduces tumor growth in vivo. Cancer Res 2002;62:5370-4.
13. Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr Opin Chem Biol 2003;7:481-9.
14. Ramotar D, Wang H. Protective mechanisms against the antitumor agent bleomycin: lessons from Saccharomyces cerevisiae. Curr Genet 2003;43:213-24.
15. Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999;5:739-45.
16. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001;19:2074-83.
17. Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 2002;20:3445-53.
18. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21:2529-36.
19. Rodrigus P. Motexafin gadolinium: a possible new radiosensitiser. Expert Opin Investig Drugs 2003;12:1205-10.
20. Magda D, Gerasimchuk N, Lecane P, Miller RA, Biaglow JE, Sessler JL. Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem Commun (Camb) 2002;22:2730-1.
21. Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001;51:1025-36.
22. Biaglow JE, Miller RA, Magda D, Lee I, Tuttle S. Inhibition of thioredoxin reductase by motexafin gadolinium: effects on PLDR. Prog Abst Radiat Res Soc 2002:107.
23. Rockwell S, Donnelly ET, Liu Y, Tang LQ. Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro. Int J Radiat Oncol Biol Phys 2002;54:536-41.
24. + ionophore nigericin. Int J Radiat Oncol Biol Phys 1991;20:281-5.
25. Karaman MW, Houck ML, Chemnick LG, et al. Comparative analysis of gene-expression patterns in human and African great ape cultured fibroblasts. Genome Res 2003;13:1619-30.
26. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
28. Biaglow JE, Donahue J, Tuttle S, Held K, Chrestensen C, Mieyal J. A method for measuring disulfide reduction by cultured mammalian cells: relative contributions of glutathione-dependent and glutathione-independent mechanisms. Anal Biochem 2000;281:77-86.
29. Gee KR, Zhou ZL, Ton-That D, Sensi SL, Weiss JH. Measuring zinc in living cells. A new generation of sensitive and selective fluorescent probes. Cell Calcium 2002;31:245-51.
30. Takeda J, Yano H, Eng S, Zeng Y, Bell GI. A molecular inventory of human pancreatic islets: sequence analysis of 1000 cDNA clones. Hum Mol Genet 1993;2:1793-8.
31. Giedroc DP, Chen X, Apuy JL. Metal response element (MRE)-binding transcription factor-1 (MTF-1): structure, function, and regulation. Antioxid Redox Signal 2001;3:577-96.
32. Lichtlen P, Schaffner W. Putting its fingers on stressful situations: the heavy metal-regulatory transcription factor MTF-1. Bioessays 2001;23:1010-7.
33. Lichtlen P, Wang Y, Belser T, et al. Target gene search for the metal-responsive transcription factor MTF-1. Nucleic Acids Res 2001;29:1514-23.
34. Andrews GK. Cellular zinc sensors: MTF-1 regulation of gene expression. Biometals 2001;14:223-37.
35. Sauer JM, Waalkes MP, Hooser SB, Kuester RK, McQueen CA, Sipes IG. Suppression of Kupffer cell function prevents cadmium induced hepatocellular necrosis in the male Sprague-Dawley rat. Toxicology 1997;121:155-64.
36. Andrews GK. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol 2000;59:95-104.
37. Nordberg GF. Modulation of metal toxicity by metallothionein. Biol Trace Elem Res 1989;21:131-5.
38. Achanzar WE, Achanzar KB, Lewis JG, Webber MM, Waalkes MP. Cadmium induces c-myc, p53, and c-jun expression in normal human prostate epithelial cells as a prelude to apoptosis. Toxicol Appl Pharmacol 2000;164:291-300.
39. Holmgren A. Thioredoxin. Annu Rev Biochem 1985;54:237-71.
40. Lenartowicz E, Wudarczyk J. Enzymatic reduction of 5,5′-dithiobis- (2-nitrobenzoic acid) by lysate of rat liver mitochondria. Int J Biochem Cell Biol 1995;27:831-7.
41. Rigobello MP, Callegaro MT, Barzon E, Benetti M, Bindoli A. Purification of mitochondrial thioredoxin reductase and its involvement in the redox regulation of membrane permeability. Free Radic Biol Med 1998;24:370-6.
42. Langmade SJ, Ravindra R, Daniels PJ, Andrews GK. The transcription factor MTF-1 mediates metal regulation of the mouse ZnT1 gene. J Biol Chem 2000;275:34803-9.
43. Palmiter RD. Protection against zinc toxicity by metallothionein and zinc transporter 1. Proc Natl Acad Sci U S A 2004;101:4918-23.
44. 2 in vitro is modulated by metallothionein. Mol Cell Biol 2003;23:8471-85.
45. Maret W, Vallee BL. Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci U S A 1998;95:3478-82.
46. Jacob C, Maret W, Vallee BL. Control of zinc transfer between thionein, metallothionein, and zinc proteins. Proc Natl Acad Sci U S A 1998;95:3489-94.
47. Murray JI, Whitfield ML, Trinklein ND, Myers RM, Brown PO, Botstein D. Diverse and specific gene expression responses to stresses in cultured human cells. Mol Biol Cell 2004;15:2361-74.
48. Yoneda K, Chang MM, Chmiel K, Chen Y, Wu R. Application of high-density DNA microarray to study smoke- and hydrogen peroxide-induced injury and repair in human bronchial epithelial cells. J Am Soc Nephrol 2003;14:S284-9.
49. 2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med 2002;33:1419-32.
50. Chuang YY, Chen Y, Gadisetti, et al. Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res 2002;62:6246-54.
51. Morgan KT, Ni H, Brown HR, et al. Application of cDNA microarray technology to in vitro toxicology and the selection of genes for a real-time RT-PCR-based screen for oxidative stress in Hep-G2 cells. Toxicol Pathol 2002;30:435-51.
52. Suzuki T, Spitz DR, Gandhi P, Lin HY, Crawford DR. Mammalian resistance to oxidative stress: a comparative analysis. Gene Expr 2002;10:179-91.
53. Arner ES, Nordberg J, Holmgren A. Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem Biophys Res Commun 1996;225:268-74.
54. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000;267:6102-9.
55. Smart DK, Ortiz KL, Mattson D, et al. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res 2004;64:6716-24.
56. Cherkasova EV. The effect of zinc on oxygen consumption, phagocytosis and the development of Pliss lymphosarcoma. Vopr Onkol 1969;15:81-5.
57. Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999;40:200-7.
58. Feng P, Li TL, Guan ZX, Franklin RB, Costello LC. Effect of zinc on prostatic tumorigenicity in nude mice. Ann N Y Acad Sci 2003;1010:316-20.
59. Yin H, Smith M, Glass J. Stable expression of C/EBPα in prostate cancer cells down-regulates metallothionein and increases zinc-induced toxicity. Prostate 2005;62:209-16.